Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective cohort study to evaluate the incidence of major bleeding in morbidly obese patients treated with a high-fixed dose unfractionated heparin compared to high-fixed dose enoxaparin

Next Previous
Trial Profile

A retrospective cohort study to evaluate the incidence of major bleeding in morbidly obese patients treated with a high-fixed dose unfractionated heparin compared to high-fixed dose enoxaparin

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enoxaparin sodium (Primary) ; Heparin (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use

Most Recent Events

  • 27 Dec 2019 Primary endpoint (Major Bleed Event, in the unfractionated heparin group compared to the enoxaparin group, OR (95% CI)) has been met, according to results published in the American Journal of Medicine
  • 27 Dec 2019 New trial record
  • 17 Dec 2019 Results published in the American Journal of Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top